CrystalGenomics, Inc. (083790.KQ)
KRW 2545.0
(0.99%)
KRW 2545.0
(0.99%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 32.36 Billion KRW | 30.58% |
| 2022 | 24.3 Billion KRW | -25.72% |
| 2021 | 26.75 Billion KRW | 47.14% |
| 2020 | 23.05 Billion KRW | 455.62% |
| 2019 | 15.36 Billion KRW | -0.34% |
| 2018 | 9.22 Billion KRW | 13.75% |
| 2017 | 15.25 Billion KRW | 3.13% |
| 2016 | 13.75 Billion KRW | 5.17% |
| 2015 | 9.81 Billion KRW | 8.67% |
| 2014 | 11.76 Billion KRW | 4.61% |
| 2013 | 10.83 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | -7.82 Billion KRW | 30.55% |
| 2024 Q1 | -5.99 Billion KRW | 3.22% |
| 2023 FY | 32.89 Billion USD | 30.58% |
| 2023 Q1 | 8.45 Billion USD | 12.86% |
| 2023 Q3 | 8.5 Billion USD | -20.77% |
| 2023 Q2 | 10.73 Billion KRW | 26.84% |
| 2023 Q4 | 5.8 Billion USD | -31.67% |
| 2022 FY | 25.19 Billion USD | -25.72% |
| 2022 Q3 | 1.65 Billion USD | 0.0% |
| 2022 Q1 | 1.22 Billion USD | 5.38% |
| 2022 Q4 | 7.49 Billion USD | 353.75% |
| 2021 Q4 | 1.15 Billion USD | -23.98% |
| 2021 FY | 33.91 Billion USD | 47.14% |
| 2021 Q1 | 1.11 Billion USD | 4.81% |
| 2021 Q3 | 1.52 Billion USD | 0.0% |
| 2020 Q1 | 998.97 Million USD | -0.21% |
| 2020 Q3 | 1.39 Billion USD | 0.0% |
| 2020 Q4 | 1.06 Billion USD | -23.98% |
| 2020 FY | 23.05 Billion USD | 455.62% |
| 2019 Q1 | 944.49 Million USD | 2.1% |
| 2019 Q3 | 1.34 Billion USD | 0.0% |
| 2019 FY | 4.14 Billion USD | -0.34% |
| 2019 Q4 | 1 Billion USD | -25.83% |
| 2018 Q4 | 925.08 Million USD | -29.74% |
| 2018 FY | 4.16 Billion USD | 13.75% |
| 2018 Q3 | 1.31 Billion USD | 0.0% |
| 2018 Q1 | 877.2 Million USD | -18.17% |
| 2017 FY | 3.65 Billion USD | 3.13% |
| 2017 Q1 | 848.84 Million USD | 3.32% |
| 2017 Q3 | 1.14 Billion USD | 0.0% |
| 2017 Q4 | 1.07 Billion USD | -6.5% |
| 2016 FY | 3.54 Billion USD | 5.17% |
| 2016 Q4 | 821.56 Million USD | -24.72% |
| 2016 Q3 | 1.09 Billion USD | 0.0% |
| 2016 Q1 | 834.08 Million USD | 3.24% |
| 2015 Q3 | 1.05 Billion USD | 0.0% |
| 2015 Q1 | 788.83 Million USD | 2.7% |
| 2015 FY | 3.37 Billion USD | 8.67% |
| 2015 Q4 | 807.93 Million USD | -23.66% |
| 2014 FY | 3.1 Billion USD | 4.61% |
| 2014 Q1 | 738 Million USD | 5.13% |
| 2014 Q3 | 965.01 Million USD | 0.0% |
| 2014 Q4 | 768.09 Million USD | -20.41% |
| 2013 Q1 | 686.68 Million USD | 6.56% |
| 2013 Q4 | 701.97 Million USD | -27.49% |
| 2013 FY | 2.96 Billion USD | 0.0% |
| 2013 Q3 | 968.15 Million USD | 0.0% |
| 2012 Q4 | 644.41 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 70.569% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -312.575% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 41.86% |
| Bioneer Corporation | 204.55 Billion KRW | 84.176% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -318.206% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 50.44% |
| Helixmith Co., Ltd | 37.36 Billion KRW | 13.374% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 88.679% |
| Medy-Tox Inc. | 110.88 Billion KRW | 70.808% |
| Peptron, Inc. | 16.65 Billion KRW | -94.337% |
| Amicogen, Inc. | 52.82 Billion KRW | 38.72% |
| Genexine, Inc. | 41.62 Billion KRW | 22.241% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -100.229% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 67.177% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 20.924% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 63.809% |
| SillaJen, Inc. | 5.11 Billion KRW | -533.184% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -26.128% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | 8.169% |
| Genomictree Inc. | 16.26 Billion KRW | -99.017% |
| MedPacto, Inc. | 26.91 Billion KRW | -20.248% |
| D&D Pharmatech | 32.16 Billion KRW | -0.643% |
| EASY BIO,Inc. | 29.67 Billion KRW | -9.093% |
| GI Innovation, Inc. | 57.59 Billion KRW | 43.795% |